Last reviewed · How we verify
ASP1128
At a glance
| Generic name | ASP1128 |
|---|---|
| Also known as | MA-0217 |
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery (PHASE2)
- A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP1128 CI brief — competitive landscape report
- ASP1128 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI